论文信息 - Serious QT interval prolongation with ranolazine and amiodarone.

Serious QT interval prolongation with ranolazine and amiodarone.

a Pharmacology, Therapeutics and Toxicology Department, UniversitatAutonoma de Barcelona, 08193 Bellaterra (Cerdanyola del Valles), Spain b Clinical Pharmacology Department, Hospital Universitari Germans TriasiPujol, Carretera de Canyet s/n, 08916 Badalona, Spain c FundacioInstitutCatala de Farmacologia, PasseigValld'Hebron 119-129, 08035 Barcelona, Spain d Catalan Centre of Pharmacovigilance, Barcelona, Spain

[1] P. Foley,et al. Amiodarone--avoid the danger of torsade de pointes. , 2008, Resuscitation.

[2] M. Jerling. Clinical Pharmacokinetics of Ranolazine , 2006, Clinical pharmacokinetics.

[3] K. Letsas,et al. QT Interval Prolongation and Torsades de Pointes Due to a Coadministration of Metronidazole and Amiodarone , 2005, Pacing and clinical electrophysiology : PACE.

[4] D. Pierce,et al. Ranolazine-Tacrolimus Interaction , 2010, The Annals of pharmacotherapy.

[5] A. Skene,et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. , 2007, JAMA.

[6] K. Koskinas,et al. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. , 2012, The American journal of cardiology.

[7] S. Hohnloser,et al. Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.

[8] A. Camm. Safety considerations in the pharmacological management of atrial fibrillation. , 2008, International journal of cardiology.

[9] David Zeltser,et al. Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.